ZNTLZentalis Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Zentalis Pharmaceuticals, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZNTLThis | $225M#9 | — | 1.6x#7 | — | -100.0%#10 | 17.4%#7 | — | -95.4%#12 | — | — | 120.8%#2 | — |
| MGNX | $258M#2 | — | 6.0x#11 | 1.7x#4 | -0.3%#6 | -11.4%#12 | -48.7%#5 | -0.2%#5 | — | — | 162.7%#1 | — |
| FHTX | $248M#3 | — | — | 8.0x#6 | 36.8%#3 | 14.2%#8 | -279.5%#6 | — | — | — | -14.2%#10 | — |
| AKBA | $242M#5 | — | 9.7x#13 | 1.0x#3 | 47.5%#2 | 92.4%#4 | 9.9%#3 | -21.2%#7 | — | — | -68.8%#15 | — |
| RNAC | $242M#4 | — | — | 606.2x#10 | -99.0%#9 | -68.3%#15 | -35851.3%#10 | — | — | — | -12.7%#9 | — |
| ALXO | $241M#6 | — | 1.8x#10 | — | — | 24.6%#6 | — | -74.7%#10 | -84.4%#2 | — | 64.6%#5 | — |
| WHWK | $232M#7 | — | 1.3x#5 | 32.5x#8 | -72.5%#8 | 67.7%#5 | -1601.1%#9 | -11.3%#6 | — | — | 107.9%#3 | — |
| NATR | $232M#8 | 13.2x#2 | 1.7x#8 | 0.5x#1 | 5.7%#5 | 153.7%#2 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#11 | — |
| SIGA | $220M#10 | — | 1.3x#6 | 2.3x#5 | -31.8%#7 | -60.7%#14 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#13 | 19.6%#1 |
| KROS | $219M#11 | — | 0.8x#2 | 0.9x#2 | 6775.0%#1 | 146.4%#3 | 27.7%#1 | 33.2%#1 | — | — | -29.1%#12 | — |
| ELDN | $214M#12 | — | 6.5x#12 | — | — | -26.1%#13 | — | -138.2%#13 | — | — | 8.4%#8 | — |
| BRVE | $2.5B#1 | — | — | — | — | — | — | — | — | — | — | — |
| PEPG | $203M#13 | — | 1.7x#9 | — | — | 0.4%#11 | — | -75.0%#11 | — | — | 56.7%#6 | — |
| NKTX | $198M#14 | — | 0.8x#1 | — | — | 4.3%#10 | — | -42.0%#8 | — | — | 43.7%#7 | — |
| TNXP | $196M#15 | — | 0.9x#3 | 14.9x#7 | 29.8%#4 | 4.6%#9 | -959.1%#8 | -55.8%#9 | -234.8%#3 | — | -58.7%#14 | — |
| ORMP | $196M#16 | 1.1x#1 | 1.0x#4 | 97.8x#9 | — | 573.1%#1 | -754.4%#7 | 0.0%#4 | -4.4%#1 | — | 106.6%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice